Physician profile
John D Crawford
NPI 1568406551
$15,851.35
in general payments reported to CMS, 2019-2025
41 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,402 · 2020: $2,147 · 2021: $3,163 · 2022: $681 · 2023: $1,771 · 2024: $2,583 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,459.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,120.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,938.71 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $1,427.54 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $1,229.55 | 2019-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $886.18 | 2019-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $720.84 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $644.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $620.10 | 2019-2024 | Verquvo, Winrevair |
| Acadia Pharmaceuticals INC | $611.36 | 2024 | Nuplazid |
| Abbvie INC. | $510.98 | 2019-2023 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $462.63 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $370.16 | 2019-2021 | |
| Esperion Therapeutics, INC. | $292.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $291.72 | 2019-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.